Table 1.
Summary of genome-wide homozygosity measures by GWAS and case-control status*
| Subtype | Study | No. cases |
No. controls |
Median ROH total length (kb) |
IQR ROH total length (kb) |
Median number of ROH |
IQR number of ROH |
Median FROH |
IQR FROH | Median F3 | IQR F3 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CLL | NCI | Cases | 2140 | 18593 | 13057-25486 | 7 | 5-9 | 0.62% | 0.44%-0.79% | 2.57 × 10−3 | −1.34 × 10−3−7.49 × 10−3 |
| Controls | 6105 | 18045 | 12674-24396 | 7 | 5-9 | 0.60% | 0.42%-0.81% | 1.48 × 10−3 | −2.07 × 10−3−5.36 × 10−3 | ||
| GEC | Cases | 387 | 23014 | 16496-29054 | 8 | 6-10 | 0.77% | 0.55%-0.97% | 6.41 × 10−4 | −3.66 × 10−3−4.85 × 10−3 | |
| Controls | 294 | 21920 | 14852-28391 | 8 | 6-10 | 0.73% | 0.50%-0.95% | −6.99 × 10−4 | −4.90 × 10−3−3.06 × 10−3 | ||
| UCSF2 | Cases | 213 | 12993 | 7893-19530 | 4 | 3-6 | 0.43% | 0.26%-0.65% | 2.73 × 10−3 | −0.63 × 10−3−8.83 × 10−3 | |
| Controls | 746 | 12173 | 7523-17111 | 4 | 3-6 | 0.41% | 0.25%-0.57% | 1.51 × 10−3 | −2.25 × 10−3−5.72 × 10−3 | ||
| Utah | Cases | 321 | 18806 | 13535-24431 | 7 | 5-9 | 0.63% | 0.45%-0.81% | 3.69 × 10−4 | −2.79 × 10−3−4.71 × 10−3 | |
| Controls | 403 | 17452 | 12288-22866 | 6 | 5-8 | 0.58% | 0.41%-0.76% | 9.47 × 10−4 | −2.09 × 10−3−3.89 × 10−3 | ||
| DLBCL | NCI | Cases | 2621 | 18046 | 12671-24990 | 7 | 5-9 | 0.60% | 0.42%-0.83% | 2.11 × 10−3 | −1.48 × 10−3−6.54 × 10−3 |
| Controls | 6105 | 18199 | 12753-24519 | 7 | 5-9 | 0.61% | 0.43%-0.82% | 1.46 × 10−3 | −2.05 × 10−3−5.39 × 10−3 | ||
| Mayo | Cases | 393 | 16586 | 12167-21774 | 6 | 5-8 | 0.55% | 0.41%-0.73% | 1.67 × 10−4 | −3.03 × 10−3−3.07 × 10−3 | |
| Controls | 172 | 16451 | 11368-23319 | 6 | 4-8 | 0.55% | 0.38%-0.78% | 2.19 × 10−4 | −2.55 × 10−3−2.94 × 10−3 | ||
| UCSF2 | Cases | 253 | 11535 | 5957-19153 | 4 | 3-6 | 0.38% | 0.20%-0.64% | 1.69 × 10−3 | −1.62 × 10−3−6.60 × 10−3 | |
| Controls | 745 | 12182 | 7554-17158 | 4 | 3-6 | 0.41% | 0.25%-0.57% | 1.48 × 10−3 | −2.20 × 10−3−5.82 × 10−3 | ||
| GELA/EPIC | Cases | 547 | 15526 | 10391-21466 | 6 | 4-7 | 0.52% | 0.35%-0.72% | 1.27 × 10−3 | −2.27 × 10−3−5.00 × 10−3 | |
| Controls | 525 | 17327 | 11782-23437 | 6 | 4-8 | 0.58% | 0.39%-0.78% | 2.56 × 10−3 | −0.87 × 10−3−6.14 × 10−3 | ||
| FL | NCI | Cases | 2085 | 17838 | 12387-24319 | 7 | 5-9 | 0.59% | 0.41%-0.81% | 1.41 × 10−3 | −2.14 × 10−3−6.15 × 10−3 |
| Controls | 6105 | 18110 | 12753-24512 | 7 | 5-9 | 0.60% | 0.43%-0.82% | 1.49 × 10−3 | −2.06 × 10−3−5.41 × 10−3 | ||
| UCSF1/NHS | Cases | 119 | 17058 | 12645-22150 | 7 | 5-8 | 0.57% | 0.42%-0.74% | 8.51 × 10−5 | −3.57 × 10−3−3.05 × 10−3 | |
| Controls | 340 | 17144 | 12100-24513 | 6.5 | 5-9 | 0.57% | 0.40%-0.82% | 6.35 × 10−4 | −3.05 × 10−3−4.29 × 10−3 | ||
| UCSF2 | Cases | 209 | 13621 | 8911-19655 | 5 | 3-7 | 0.45% | 0.30%-0.66% | 3.02 × 10−3 | −1.34 × 10−3−7.58 × 10−3 | |
| Controls | 745 | 12071 | 7517-17115 | 4 | 3-6 | 0.40% | 0.25%-0.57% | 1.50 × 10−3 | −2.16 × 10−3−5.76 × 10−3 | ||
| SCALE | Cases | 371 | 12582 | 7643-19776 | 5 | 3-7 | 0.42% | 0.25%-0.66% | 3.02 × 10−3 | −0.50 × 10−3−7.52 × 10−3 | |
| Controls | 790 | 12132 | 7506-17654 | 5 | 3-6 | 0.40% | 0.25%-0.59% | 1.22 × 10−3 | −1.60 × 10−3−5.00 × 10−3 | ||
| MZL | NCI | Cases | 808 | 18097 | 12831-24555 | 7 | 5-9 | 0.60% | 0.43%-0.82% | 1.83 × 10−3 | −1.54 × 10−3−7.30 × 10−3 |
| Controls | 6102 | 18268 | 12811-24623 | 7 | 5-9 | 0.61% | 0.43%-0.82% | 1.46 × 10−3 | −2.01 × 10−3−5.38 × 10−3 |
*
Median and interquartile range are provided for runs of homozygosity, fraction of runs of homozygosity, and correlation between uniting gametes (F3). GWAS: Genome-wide association studies; IQR: interquartile range; ROH: runs of homozygosity; FROH: fraction of runs of homozygosity; CLL: chronic lymphocytic leukemia; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MZL: marginal zone lymphoma.